Who are Fludeoxyglucose F18's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Slow Infusion of Rubidium-82, N-13 ammonia intravenous injection, 18F-2-fluoro-2-deoxy-D-glucose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fludeoxyglucose-f18.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fludeoxyglucose F18 — Competitive Intelligence Brief

Fludeoxyglucose F18 (Fludeoxyglucose F18) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Positron emission tomography (PET) imaging agent. Area: Oncology, Cardiology, Neurology.

marketed Positron emission tomography (PET) imaging agent Glucose metabolism / GLUT1 transporter Oncology, Cardiology, Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Fludeoxyglucose F18 (Fludeoxyglucose F18) — National Heart, Lung, and Blood Institute (NHLBI). Fludeoxyglucose F18 is a glucose analog labeled with fluorine-18 that accumulates in tissues with high metabolic activity, enabling visualization via positron emission tomography (PET) imaging.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fludeoxyglucose F18 TARGET	Fludeoxyglucose F18	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Positron emission tomography (PET) imaging agent	Glucose metabolism / GLUT1 transporter
Slow Infusion of Rubidium-82	Slow Infusion of Rubidium-82	Ochsner Health System	marketed	Positron emission tomography (PET) imaging agent	Na+/K+-ATPase pump (potassium analog)
N-13 ammonia intravenous injection	N-13 ammonia intravenous injection	Centre hospitalier de l'Université de Montréal (CHUM)	marketed	Positron emission tomography (PET) imaging agent
18F-2-fluoro-2-deoxy-D-glucose	18F-2-fluoro-2-deoxy-D-glucose	Eastern Health, Canada	phase 3	Positron emission tomography (PET) imaging agent	Glucose transporter (GLUT1) and hexokinase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Positron emission tomography (PET) imaging agent class)

Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
Eastern Health, Canada · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
Ochsner Health System · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fludeoxyglucose F18 — Competitive Intelligence Brief. https://druglandscape.com/ci/fludeoxyglucose-f18. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab